Screener
Enovis ENOV Prevention & Recovery — Cost of Goods Sold
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Enovis in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Enovis’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001420800-26-000035
| Line item | Three Months Ended / July 3, 2026 | Three Months Ended / July 4, 2025 | Six Months Ended / July 3, 2026 | Six Months Ended / July 4, 2025 |
|---|---|---|---|---|
| Prevention & Recovery: | ||||
| Net sales | $288,248 | $290,570 | $560,266 | $563,154 |
| Segment cost of sales | 124,094 | 131,336 | 249,851 | 260,100 |
| Segment research and development | 7,706 | 9,669 | 15,453 | 18,910 |
| Segment operating expense | 111,250 | 107,523 | 223,720 | 215,367 |
| Total segment expenses | 243,050 | 248,528 | 489,024 | 494,377 |
| Add: Depreciation | 5,129 | 4,689 | 10,194 | 8,857 |
| Adjusted EBITDA (non-GAAP) | $50,327 | $46,731 | $81,436 | $77,634 |
Item 1. Financial Statements
FAQ
- What is Enovis's prevention & recovery — cost of goods sold?
- Enovis (ENOV) reported prevention & recovery — cost of goods sold of $124.09M in Q2 2026.
- What does prevention & recovery — cost of goods sold mean?
- The direct costs incurred by the Prevention & Recovery segment to manufacture, distribute, and provide services for its medical products. This includes raw materials, labor, and overhead directly attributable to the production of rehabilitation and pain management devices.
Ask your AI about Enovis's prevention & recovery — cost of goods sold.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude